Acalabrutinib has received approval for specific medical uses.
What is Acalabrutinib approved to treat?
Acalabrutinib is approved for the treatment of adult patients with certain types of non-Hodgkin lymphoma (NHL). This includes patients with previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [1].
When was Acalabrutinib first approved?
The initial approval for acalabrutinib was granted for previously treated MCL in January 2019. Subsequently, it received approval for previously treated CLL/SLL in June 2019 [1].
What is the mechanism of action for Acalabrutinib?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by irreversibly binding to BTK, which is a protein found on B cells. By inhibiting BTK, acalabrutinib blocks the signaling pathways that are essential for the survival and proliferation of malignant B cells [2].
How does Acalabrutinib compare to other BTK inhibitors?
Acalabrutinib is a second-generation BTK inhibitor. Compared to first-generation BTK inhibitors like ibrutinib, acalabrutinib is designed to be more selective for BTK, potentially leading to fewer off-target side effects. Clinical trials have shown comparable efficacy with a potentially improved safety profile for acalabrutinib in certain patient populations [3].
What is the patent status for Acalabrutinib?
Information regarding the patent status and expiry dates for acalabrutinib is available through resources like DrugPatentWatch.com [4]. Patent protection is crucial for pharmaceutical companies as it grants them exclusive rights to market and sell the drug for a specified period.
What are the common side effects of Acalabrutinib?
Common side effects reported in clinical trials include fatigue, diarrhea, anemia, and bruising. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [1].
Who manufactures Acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [1].
Sources:
1. https://www.drugpatentwatch.com/drug/acalabrutinib
2. https://www.drugpatentwatch.com/drug/acalabrutinib
3. https://www.drugpatentwatch.com/drug/acalabrutinib
4. https://www.drugpatentwatch.com/drug/acalabrutinib